INVESTMENTS

The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions):



Measurement Category	Balance Sheet Location	September 29, 2018		December 31, 2017⁽²⁾
Fair value method	Prepaid expenses and other current assets	$	7.0	$	17.0
Fair value method⁽¹⁾	Other non-current assets	$	4.8	$	6.3
Equity method	Other non-current assets	$	14.1	$	4.9

(1) The September 29, 2018 equity securities are measured at fair value using the Net Asset Value practical expedient.

(2) The December 31, 2017 balances presented reflect historical recognition and measurement investment categories existing prior to the adoption of ASU 2016-01, which include available for sale and cost method securities.

The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions):



		Three Months Ended					Nine Months Ended
Measurement Category	Income Statement Location	September 29, 2018			September 30, 2017		September 29, 2018			September 30, 2017
Fair value method	Other (income) expense, net	$	0.9		$	—	$	11.6		$	—
Equity method	Other (income) expense, net	$	(1.0	)	$	0.1	$	(1.6	)	$	(0.2	)

On January 1, 2018, as a result of the adoption of ASU 2016-01 Financial Instruments - Recognition and Measurement of Financial Assets and Liabilities ("ASU 2016-01"), we made a $1.0 million cumulative-effect adjustment to Retained earnings (accumulated deficit) net of tax that consisted of net unrealized losses on previously classified available for sale securities from Other comprehensive income ("OCI").

During the nine months ended September 29, 2018, we increased our equity method investment in Zibo Xinhua - Perrigo Pharmaceutical Company Limited by $7.5 million.